United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $168,188,006.77. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Stock Down 0.0%

Shares of NASDAQ:UTHR traded down $0.24 during trading on Monday, reaching $512.88. 291,650 shares of the company traded hands, compared to its average volume of 489,537. The firm has a fifty day simple moving average of $533.08 and a 200 day simple moving average of $537.80. The firm has a market cap of $22.00 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business posted $6.41 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analyst Ratings Changes

UTHR has been the subject of several research reports. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. JPMorgan Chase & Co. increased their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, Royal Bank Of Canada decreased their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. raised its position in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 70 shares during the last quarter. Jump Financial LLC acquired a new position in United Therapeutics during the 2nd quarter worth $277,000. Cerity Partners LLC boosted its holdings in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 5,600 shares during the period. Finally, Bank of Nova Scotia boosted its holdings in United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.